• 1 Fitch MT, Manthey DE, McGinnis HD, Nicks BA, Pariyadath M. Videos in Clinical Medicine: Abscess Incision and drainage (video). N Engl J Med 2077; 357:e20.
• 2 Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin. 2010Oct;28(4):779-93.
• 3 Orman, Rob. Perianal Abscess. ERCAST, Jan 2011. http://ercast.org/perianal-abscess
• 4 Schwarz RJ, Shrestha R. Needle Aspiration of Breast Abscess. Am J Surg. 2001;l 182(2):117.
• 5 Kronfol R, Downey K. Technique of Incision and Drainage for Skin Abscess. UpToDate Online. May 2011.
• 6 Wilson W et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association and others. Circulation. 2007 Oct 9;116(15):1736-54.
• 7 Roberts, James R. Clinical Procedures in Emergency Medicine, 5th ed. 2009.
• 8 Liu C, Bayer A, Infectious Diseases Society of America, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylo- coccus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55.
• 9 O’Malley GF, Dominici P, Giraldo P, Aguilera E, Verma M, Lares C, Burger P, Williams E. Routine packing of simple cutaneous abscesses is painful and probably unnecessary. Acad Emerg Med. 2009 May;16(5):470-3.
• 10 Schmitz GR. How do you treat an abscess in the era of increased community-associated methicillin-resistant Staphylococcus aureus (MRSA)? J Emerg Med. 2011 Sep;41(3):276-81.
• 11 Walraven CJ, Lingenfelter E, Rollo J, Madsen T, Alexander DP. Diagnostic and therapeutic evaluation of community-acquired methicillin-resistant Staphylococcus Aureus (MRSA) skin and soft tissue infections in the emergency department. J Emerg Med. 2012 Apr;42(4):392-9.
For abscess I&D, most of us haven’t been thinking about antibiotic prophylaxis in patients at risk for infective endocarditis. According to my interpretation of table six of this guideline, we should be. “Antibiotic prophylaxis is reasonable for procedures on respiratory tract or infected skin, skin structures, or musculoskeletal tissue only for patients with underlying cardiac conditions associated with the highest risk of adverse outcome from IE (Table 3).”